Skip to: Content
Skip to: Site Navigation
Skip to: Search

MONDAY, NOVEMBER 23, 2009
| Subscribe to Newser's RSS feeds RSS | Follow Newser on Twitter Twitter


0

Quit-Smoking Drug Linked to Heart Trouble, Dizziness

FAA bans pilots and air controllers from using Chantix after report

Share

(Newser) – Pfizer smoking-cessation drug Chantix has been linked to nearly a thousand serious incidents in the last quarter of 2007, the Wall Street Journal reports. A report from a drug safety group found that some users of the drug—already linked to depression and suicide—suffered heart trouble, diabetes, or accidents caused by dizziness and confusion.

The FAA immediately banned pilots and air-traffic controllers from using Chantix and the study's author called for the FDA to update the popular drug's warning label. Pfizer spokesmen said that the current warning already listed the events, classifying them as "rare." The drug company noted that  5.5 million Americans have used the drug.

Pfizer's anti-smoking drug Chantix has been used by millions since its launch in 2006, but sales slipped afer reports of serious psychiatric side effects.
Pfizer's anti-smoking drug Chantix has been used by millions since its launch in 2006, but sales slipped afer reports of serious psychiatric side effects.   (innewscenterhd)
Chantix, which works by blocking the parts of the brain that get pleasure from nicotine, has been one of Pfizer's top sellers.
Chantix, which works by blocking the parts of the brain that get pleasure from nicotine, has been one of Pfizer's top sellers.   (AP Photo/Mark Lennihan, File)
A new report from a drug safety group has linked Chantix to a large number of serious incidents.
A new report from a drug safety group has linked Chantix to a large number of serious incidents.   ((c) justj0000lie)
« Prev« Prev | Next »Next » Slideshow
0 comments
VIEWING:
 
LEAVE A
COMMENT
Comment Policy
Facebook ConnectPost this comment to Facebook?

After connecting you will have the option to post your comment on your Facebook profile.